

Unless otherwise noted, comments regarding each of these applications must be received not later than January 27, 1995.

A. Federal Reserve Bank of Cleveland
(John J. Wixted, Jr., Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101:

1. *Citizens Independent Bancorp, Inc.*, Logan, Ohio; to become a bank holding company by acquiring 100 percent of the voting shares of The Citizens Bank of Logan, Logan, Ohio.

B. Federal Reserve Bank of Dallas
(Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Riverside Bancshares Inc.*, Logansport, Louisiana; to become a bank holding company by acquiring 89.46 percent of the voting shares of The Bank of Logansport, Logansport, Louisiana.

Board of Governors of the Federal Reserve System, December 27, 1994.

Jennifer J. Johnson,
Deputy Secretary of the Board.
[FR Doc. 94-32269 Filed 12-30-94; 8:45 am]
BILLING CODE 6210-01-F

Douglas J. Hanson; Change in Bank Control Notice

Acquisition of Shares of Banks or Bank Holding Companies

The notificant listed below has applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notice is available for immediate inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for the notice or to the offices of the Board of Governors. Comments must be received not later than January 17, 1995.

A. Federal Reserve Bank of Minneapolis (James M. Lyon, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

1. *Douglas J. Hanson*, Aurora, Colorado; to acquire an additional 4.32 percent, for a total of 25.01 percent, of the voting shares of Security State Bank Shares, Polson, Montana, and thereby indirectly acquire Security State Bank and Trust Company, Polson, Montana.

Board of Governors of the Federal Reserve System, December 27, 1994.

Jennifer J. Johnson,
Deputy Secretary of the Board.
[FR Doc. 94-32270 Filed 12-30-94; 8:45 am]
BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 94F-0440]

Sumitomo Chemical America, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Sumitomo Chemical America, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 2,2'-methylenebis(4-methyl-6-tert-butylphenol)monoacrylate as an antioxidant in acrylonitrile/butadiene/styrene copolymers intended for use in contact with food.

DATES: Written comments on the petitioner's environmental assessment by February 2, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS-216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3081.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 5B4443) has been filed by Sumitomo Chemical America, Inc., Specialty Chemicals, 345 Park Ave., New York City, NY 10154. The petition proposes to amend the food additive regulations in § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) to provide for the safe use of 2,2'-methylenebis(4-methyl-6-tert-butylphenol)monoacrylate as an antioxidant in acrylonitrile/butadiene/styrene copolymers complying with § 177.1020 (21 CFR 177.1020) intended for use in contact with food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental

Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before (*insert date 30 days after date of publication in the Federal Register*), submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: December 21, 1994.

Alan M. Rulis,
Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 94-32241 Filed 12-30-94; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 94E-0234]

Determination of Regulatory Review Period for Purposes of Patent Extension; Zemuron™ Injection; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting the notice that appeared in the **Federal Register** of September 15, 1994. The document announced FDA's determination of the regulatory review period for purposes of patent extension for Zeuron™ Injection (rocuronium bromide). The document was published with some errors. The document incorrectly stated: "1. *The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act became effective:* January 15, 1994. The applicant claims January 14, 1989, as